Skip to main content
Equibles
SPRO logo

SPRO · Spero Therapeutics, Inc.

Track SPRO — free

Use SPRO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SPRO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.13 +0.01 (+0.89%) At close · Sep 11
Rebalance outlook locked
Market Cap
$65.81M
Shares
58.23M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.13 Open$1.13 Day$1.13–1.15 52W close$1.12–2.98 Avg vol 30d524K Short int1.2M · 2.1% float · 3.0d Short vol21% Last earningsAug 12, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Feb 18, 2027 Est · unconfirmed · in 23 wks
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$47.00M
Trailing 12 months
Net income (TTM)
$7.38M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
12.8%
Trailing 12 months
P / E (TTM)
8.1
Trailing earnings · reciprocal yield 12.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.5%
Year over year · more shares
Price change (1Y)
-42.1%
Trailing year
Short interest
2.1%
Latest settlement · 3.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −48%
below
Price vs 50-day avg −18%
below
RSI (14) 31
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −52%
trailing
YTD return −52%
this year
Relative strength −70%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.08% of float · ▼ -16.3% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
61 holders — near 3-yr high, broad support
Squeeze score 43
elevated · 0–100
Fundamentals
Strong
Revenue growth +39%
Y/Y
EPS growth +112%
Y/Y
Free cash flow $-12.8M
Valuation P/E 8.1
in line
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −62%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−48% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
31 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.08% of float · ▼ -16.3% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
61 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $3
vs 200-day avg -48% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SPRO
Spero Therapeutics, Inc.
this stock
$65.81M -51.5% +39.2% 8.1 2.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
61
% held
37.2%
Net QoQ
+818.3K sh
Top holder
GSK plc
Held Float
View
Held by Funds
Fund positions
23
View
Short & Settlement
Short Interest Falling
Shares short
1.2M
Days to cover
3.0d
Change
-235.5K sh
View
Short Volume
Short vol %
21%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
742
Value
$913
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
59.4%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$66.8M
Net income (FY)
$8.6M
EPS diluted
$0.15
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 28, 2026
This year
12
View
Proposed Sales
Value
$65.5K
Shares
45.1K
Filed
Feb 5, 2024
View
Exempt Offerings
Offering
$9.0M
Filed
Nov 15, 2022
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
SPRO -7.4% -8.9% -52.3% -7.4% -51.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.2% -7.1% -70.2% -7.0% -63.6%
Key facts CIK 1701108 CUSIP 84833T103 13F (30d) 27 filings 27 filers Visit website